Invasive Breast Cancer, Breast Cancer
Conditions
Keywords
Neoplasms by Site, Breast Neoplasms, Breast Diseases, Breast Cancer, Cancer of Breast, Cancer of the Breast, Carcinoma
Brief summary
The purpose of this study is to evaluate whether a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is equivalent to standard post-operative external beam radiotherapy after breast conserving surgery in women with early stage breast cancer in terms of local relapse within the treated breast.
Detailed description
TARGIT is an international randomised clinical trial designed to test the hypothesis that the strategy of delivering a single dose of targeted intraoperative radiotherapy (IORT) in patients eligible for breast conserving therapy (with the addition of whole breast radiotherapy in those patients at high risk of recurrence elsewhere in the breast \[e.g. lobular carcinomas and extensive intraductal component\]) is equivalent to a conventional course of post-operative external beam radiotherapy (EBRT). The primary endpoints are local and loco-regional recurrence rates. It is a pragmatic trial in which each participating centre has the option to define more restrictive entry criteria than in the core protocol. Only centres with access to the Intrabeam® (Carl Zeiss) enter patients into the trial. Eligible patients are those with tumours of good prognosis suitable for breast conserving surgery. After giving consent patients are randomised to either IORT or to EBRT. They may receive any other adjuvant treatments as deemed necessary, except for neoadjuvant therapy. The protocol requires that patients be followed at six monthly intervals for five years and then annually.
Interventions
DEVICEIntrabeam
A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
RADIATIONPost-operative radiotherapy
All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
Sponsors
National Institute for Health Research, United Kingdom
University College, London
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 45 years or older * Operable invasive breast cancer (T1 and small T2, N0-1, M0) confirmed by cytological or histological examination * Suitable for breast conserving surgery * Previously diagnosed and treated contralateral breast cancer may be entered but will be randomised to a separate stratum. * Available for regular follow-up for at least ten years. Note: Individual centres may wish to restrict entry to a more exactly defined subset of patients, in which case, only patients with these characteristics may be entered by that particular centre. For example, centres may decide at outset to recruit only women over 50 or even over 65 years of age. Such policies must be pre-defined in writing and approved by the International Steering Committee.
Exclusion criteria
* More than one obvious cancer in the same breast as diagnosed by clinical examination, mammography or ultrasonography. * Bilateral breast cancer at the time of diagnosis. * Ipsilateral breast had a previous cancer and/or irradiation. * Patients known to have BRCA2 gene mutations, but testing for gene mutations is not required * Lobular cancer or Extensive intraductal Component (EIC =\>25% of the tumour is intraductal) on core biopsy or initial pathology (if performed) * Patients undergoing primary medical treatment (hormones or chemotherapy) as initial treatment with neoadjuvant intent of reducing tumour size should be excluded; those given short duration (up to 4 weeks) systemic therapy can be included. * Patients presenting with gross nodal disease, considered to be clinically malignant or proven cytologically or by scanning. In general, 4 or more positive nodes or extranodal spread are not suitable for Targit alone and should receive EBRT as well. However, individual centres may decide that anything more than micrometastasis should receive EBRT. * Patients with any severe concomitant disease that may limit their life expectancy. * Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater. * Any factor included as exclusion criterion in the local centre's Treatment Policy. This is particularly relevant to patients entered into the post pathology stratum. * No more than 30 days can have elapsed between last breast cancer surgery (not axillary) and entry into the trial for patients in the post-pathology stratification.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local relapse within the treated breast. | 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months |
Secondary
| Measure | Time frame |
|---|---|
| Site of relapse within the breast | 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months |
| Relapse-free survival and overall survival | 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months |
| Local toxicity/morbidity | 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months |
Countries
United Kingdom
Outcome results
None listed